Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.500NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.500NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.500NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.500NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.500NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.500ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.511ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.511ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.511NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.511NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.511NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.511NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.511NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.511ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.428.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.428.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.428.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-18666.6China
B.1.428.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.428.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-18427.7US
B.1.428.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.428.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.428.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.506ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.506ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.506NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.506NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.506NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.506NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.506NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.506ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.482ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.482ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.482NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.482NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.482NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.482NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.482NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.482ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.1.335ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.1.335ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.1.335NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.1.335NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.1.335NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.335NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.1.335NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.1.335ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.36.36ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.36.36ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.36.36NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.36.36NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used